SEARCH

SEARCH BY CITATION

References

  • 1
    Croghan A, Heitkemper MM. Recognizing and managing patients with irritable bowel syndrome. J Am Acad Nurse Pract 2005; 17: 519.
  • 2
    Wilson S, Roberts L, Roalfe A et al. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 2004; 54: 495502.
  • 3
    Gwee KA, Wee S, Wong ML et al. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. Am J Gastroenterol 2004; 99: 92431.
    Direct Link:
  • 4
    Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 19105.
  • 5
    Camilleri M, Northcutt AR, Kong S et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 103540.
  • 6
    Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003; 15: 7986.
  • 7
    Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 173340.
  • 8
    Miyata K, Ito H, Fukudo S. Involvement of the 5-HT3 receptor in CRH-induce defecation in rats. Am J Physiol 1998; 274: G82731.
  • 9
    Hirata T, Funatsu T, Keto Y et al. Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents. J Pharmacol Sci 2008; 106: 26470.
  • 10
    Hirata T, Keto Y, Nakata M et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil 2008; 20: 55765.
  • 11
    Matsueda K, Harasawa S, Hongo M et al. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 2008; 77: 22535.
  • 12
    Matsueda K, Harasawa S, Hongo M et al. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 120211.
  • 13
    Jones RH, Holtmann G, Rodrigo L et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 141927.
  • 14
    Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16: 54753.
  • 15
    Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006; 130: 148091.
  • 16
    Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today 2002; 38: 7589.
  • 17
    Gan TJ. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs 2005; 19: 22538.
  • 18
    Andresen V, Montori VM, Keller J et al. Effects of 5-HT3 antagonists on symptom relief and constipation in non-constipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008; 6: 54555.
  • 19
    Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: A meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther 2008; 30: 884901.